GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AP Biosciences Inc (ROCO:6945) » Definitions » Liabilities-to-Assets

AP Biosciences (ROCO:6945) Liabilities-to-Assets : 0.06 (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is AP Biosciences Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. AP Biosciences's Total Liabilities for the quarter that ended in Dec. 2024 was NT$104.38 Mil. AP Biosciences's Total Assets for the quarter that ended in Dec. 2024 was NT$1,727.14 Mil. Therefore, AP Biosciences's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2024 was 0.06.


AP Biosciences Liabilities-to-Assets Historical Data

The historical data trend for AP Biosciences's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AP Biosciences Liabilities-to-Assets Chart

AP Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Liabilities-to-Assets
0.01 0.04 - 0.12 0.06

AP Biosciences Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Liabilities-to-Assets Get a 7-Day Free Trial - 0.10 0.12 0.06 0.06

Competitive Comparison of AP Biosciences's Liabilities-to-Assets

For the Biotechnology subindustry, AP Biosciences's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AP Biosciences's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AP Biosciences's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where AP Biosciences's Liabilities-to-Assets falls into.


;
;

AP Biosciences Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

AP Biosciences's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2024 is calculated as:

Liabilities-to-Assets (A: Dec. 2024 )=Total Liabilities/Total Assets
=104.381/1727.138
=0.06

AP Biosciences's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2024 is calculated as

Liabilities-to-Assets (Q: Dec. 2024 )=Total Liabilities/Total Assets
=104.381/1727.138
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AP Biosciences  (ROCO:6945) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


AP Biosciences Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of AP Biosciences's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


AP Biosciences Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Park Street, 17th Floor, Taipei, TWN
AP Biosciences Inc is a clinical-stage bispecific antibody new drug research and development company. It has developed a series of antibody and protein lead drugs through a self-designed technology platform for unmet medical needs, focusing on Specific targets associated with diseases to deliver safe, effective and cost-effective medicines.

AP Biosciences Headlines

No Headlines